venture fund, Lilly and Andreessen Horowitz

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...
Forty submissions, weeks of polls and several thousand votes from Herald-Leader subscribers have finally brought us to this ...
Though we’re well into the winter season, Lilly Pulitzer always finds a way to get us excited for spring and summer. The ...
Patricia Clarkson is forgettable in tonally confusing 'Lilly,' full of intrusively edited archival material and curious ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...